Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01205373
First received: September 17, 2010
Last updated: October 31, 2013
Last verified: October 2013

September 17, 2010
October 31, 2013
September 2010
October 2010   (final data collection date for primary outcome measure)
  • Individual time course profiles of 14C-radioactivity (in nmol eq/L or nmol eq/kg for faeces) in whole blood, plasma, urine, and faeces [ Time Frame: up to 336 h post treatment ] [ Designated as safety issue: No ]
  • Individual time course profiles of BI 671800 and its major metabolite CD6384 in plasma and urine [ Time Frame: up to 336 h post treatment ] [ Designated as safety issue: No ]
  • Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces [ Time Frame: up to 336 h post treatment ] [ Designated as safety issue: No ]
  • Elucidation of metabolite structures and identification of major metabolites in plasma, urine, and faeces (if feasible) in comparison with various animal species (to be presented in a separate report) [ Time Frame: up to 336 h post treatment ] [ Designated as safety issue: No ]
  • Cblood cells/Cplasma ratio of 14C-radioactivity [ Time Frame: up to 168 h post treatment ] [ Designated as safety issue: No ]
  • concentrations of BI 671800 and its metabolite CD6384 in plasma and urine [ Time Frame: up to 336 h post treatment ] [ Designated as safety issue: No ]
  • concentrations of 14C-radioactivity in whole blood, plasma, urine, and faeces [ Time Frame: up to 336 h post treatment ] [ Designated as safety issue: No ]
  • Individual time course profiles of 14C-radioactivity (in nmol eq/L or nmol eq/kg for faeces) in whole blood, plasma, urine, and faeces [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Individual time course profiles of BI 671800 and its major metabolite CD6384 in plasma and urine [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Elucidation of metabolite structures and identification of major metabolites in plasma, urine, and faeces (if feasible) in comparison with various animal species (to be presented in a separate report) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Cblood cells/Cplasma ratio of 14C-radioactivity [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Estimation of pharmacokinetic parameters using non-compartmental methods: concentrations of BI 671800 and its metabolite CD6384 in plasma and urine ¿ concentrations of 14C-radioactivity in whole blood, plasma, urine, and faeces [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01205373 on ClinicalTrials.gov Archive Site
  • Changes from Baseline in Vital signs (pulse rate) [ Time Frame: up to 23 days post treatment ] [ Designated as safety issue: No ]
  • Changes from Baseline in Physical examination [ Time Frame: up to 23 days post treatment ] [ Designated as safety issue: No ]
  • Changes from Baseline in Vital signs (blood pressure) [ Time Frame: up to 23 days post treatment ] [ Designated as safety issue: No ]
  • Changes from Baseline in 12-lead electrocardiogram (ECG) [ Time Frame: up to 23 days post treatment ] [ Designated as safety issue: No ]
  • Changes from Baseline in Clinical laboratory tests [ Time Frame: up to 23 days post treatment ] [ Designated as safety issue: No ]
  • Occurrence of Adverse Events [ Time Frame: up to 23 days post treatment ] [ Designated as safety issue: No ]
  • Assessment of tolerability by investigator [ Time Frame: up to 23 days post treatment ] [ Designated as safety issue: No ]
  • Vital signs (pulse rate) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Physical examination [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Vital signs (blood pressure) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • 12-lead electrocardiogram (ECG) [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Clinical laboratory tests [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Assessment of tolerability by investigator [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Phase I Trial to Investigate the Metabolism and Pharmacokinetics as Well as Safety and Tolerability of a Single Dose BI671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers
A Phase I Trial to Investigate the Metabolism and Pharmacokinetics of an Open-label Single Dose of 400 mg [14C]BI 671800 HEA Administered as an Oral Solution of the Choline Salt in Healthy Male Volunteers.

The main objectives of the present study are to investigate the basic pharmacokinetics of BI 671800, its major metabolite CD6384, and 14C-radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of 400 mg [14C]BI 671800 HEA to healthy male volunteers. Secondary objectives are to evaluate the safety and tolerability following a single oral dose of 400 mg [14C]BI 671800 HEA to healthy male volunteers.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Healthy
Drug: BI 671800
High dose oral drinking solution
Experimental: BI 671800 high dose
Oral drinking solution
Intervention: Drug: BI 671800
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
Not Provided
October 2010   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Healthy males according to a complete medical history, including the physical examination (to be performed at Day -1), vital signs (blood pressure, pulse rate), 12-lead Electrocardiogram (ECG), and clinical laboratory tests
  2. Age 18 to 55 years, inclusive
  3. Body mass index 18.0 to 30.0 kg/m2, inclusive
  4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria:

  1. Any finding of the medical examination (including blood pressure, pulse rate, and ECG) deviating from normal and of clinical relevance
  2. Any evidence of a clinically relevant concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. History of relevant orthostatic hypotension, fainting spells, or blackouts
  6. Chronic or relevant acute infections
  7. History of relevant allergy/hypersensitivity (including allergy to study drug or its excipients)
  8. Use of any prescription drugs 30 days prior to screening.
  9. Use of any over-the-counter, non-prescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to Check-in, unless deemed acceptable by the Investigator
  10. Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
  11. Smoker (>10 cigarettes or >3 cigars or >3 pipes/day) or positive urine cotinine test at screening and check-in (Day -1)
  12. Inability to refrain from smoking during the stay in the trial centre
  13. Alcohol abuse (more than on average 2 units of alcoholic beverages per day or more than 14 units per week. One unit equals 1 pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or one shot (25 mL) of 40% spirit, or positive urine alcohol test at screening or check-in (Day -1)
  14. Drug abuse
  15. Blood donation (>100 mL within 60 days prior to study drug administration or during the trial)
  16. Excessive physical activity (within 1 week prior to administration or during the trial until follow-up examination)
  17. Any laboratory value outside the reference range that is of clinical relevance according to the investigator
  18. Inability to comply with dietary regimen of study centre
  19. A marked baseline prolongation of QT or QTc interval, history of additional risk factors for torsade de pointes (e.g. heart failure, hypokalaemia, family history of long QT syndrome)
  20. Veins unsuitable for blood sampling
  21. Exposure to diagnostic radiation for occupational reasons or during participation in a clinical trial in the previous year (except dental X-rays and plain X-rays of thorax and bony skeleton [excluding spinal column])
  22. Irregular defecation pattern (less than once per day)
  23. Unwillingness to use adequate contraception (condom plus another form of contraception e.g. spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the entire study from the time of the first intake of study drug until 3 months after the last intake
  24. Any laboratory value outside the reference range that is of clinical relevance, especially repeated Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyltransferase (GGT), alkaline phosphatase, or total bilirubin above upper limit of normal at screening and not resolved before dosing
  25. Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval within 10 days prior to administration or during the trial, and Cytochrome P-450 (CYP)2C8 substrates such as amiodarone, amodiaquine, paclitaxel, rosiglitazone, pioglitazone and repaglinide or CYP2C9 such as warfarin, tolbutamide, phenytoin, losartan, acenocoumarol within 1 month or six half lives (whichever is greater)
Male
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01205373
1268.7, 2009-016370-32
Not Provided
Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP